紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响  

Curative effect of paclitaxel combined with carboplatin regimen in neoadjuvant chemotherapy of triple-negative breast cancer and the impact on pathological changes

作　　者：陈艳宇[1] 傅思莹[2] 赵文珍 龙中华 周扬帆[1] 彭芳[1] CHEN Yan-Yu;FU Si-Ying;ZHAO Wen-Zhen(The Second People's Hospital of Guangdong,Guangdong Provincial Emergency Hospital,Guangzhou,Guangdong 510317,China)

机构地区：[1]广东省第二人民医院广东省应急医院,广东广州510317 [2]广州中医药大学第一附属医院,广东广州510405

出　　处：《中国妇幼保健》2021年第7期1477-1480,共4页Maternal and Child Health Care of China

基　　金：广东省医学科学技术研究基金项目(B2017096)。

摘　　要：目的探讨紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗疗效及对患者病理变化的影响,为临床合理选择化疗方案提供参考依据。方法选择广东省第二人民医院及广州中医药大学第一附属医院84例三阴性乳腺癌患者作为研究对象(收治时间范围为2018年1-12月),患者分组采用单双号法进行,双号为观察组,单号为对照组,每组42例,对照组采用紫杉醇联合环磷酰胺、表柔比星胺方案治疗,观察组采用紫杉醇联合卡铂方案治疗,对比两组患者化疗后手术切除标本的Miller&Payne病理学分级改变、治疗总有效率及化疗不良反应发生率。结果治疗后,观察组患者Miller&Payne病理学分级Ⅰ级率(4.76%)、Ⅱ级率(4.76%)显著低于对照组(23.81%)、(35.71%),观察组患者Ⅳ级率(33.33%)、Ⅴ级率(35.71%)显著高于对照组(9.52%)、(7.14%);观察组患者治疗总有效率(85.71%)高于对照组(71.43%),两组对比差异有统计学意义(均P<0.05);观察组患者化疗不良反应发生率(9.52%)与对照组(11.90%)对比差异无统计学意义(P>0.05)。结论在三阴性乳腺癌新辅助化疗中应用紫杉醇联合卡铂方案对患者进行治疗,不仅能有效提高患者治疗疗效和促进其乳腺癌病灶降期,且不良反应发生率较低。Objective To explore the curative effect of paclitaxel combined with carboplatin regimen in neoadjuvant chemotherapy of triple-negative breast cancer and the impact on pathological changes,provide a reference basis for clinical reasonable selection of chemotherapy regimens.Methods From January to December in 2018,84 patients with triple-negative breast cancer were selected from the Second People’s Hospital of Guangdong and the First Affiliated Hospital of Traditional Chinese Medicine University of Guangzhou,then they were divided into observation group(even number)and control group(odd number)according to odd or even number method,42 patients in each group.The patients in control group were treated by paclitaxel combined with cyclophosphamide and epirubicin;the patients in observation group were treated by paclitaxel combined with carboplatin regimen.The changes of Miller&Payne pathological grades of resected samples,the total effective rates of treatment,and the incidence rates of adverse reactions of chemotherapy in the two groups were compared.Results After treatment,the rates of Miller&Payne pathological gradeⅠandⅡin observation group were 4.76%and 4.76%,respectively,which were statistically significantly lower than those in control group(23.81%,35.71%),the rates of Miller&Payne pathological gradeⅣandⅤin observation group were 33.33%and 35.71%,respectively,which were statistically significantly higher than those in control group(9.52%,7.14%),the total effective rate of treatment in observation group was 85.71%,which was statistically significantly higher than that in control group(71.43%)(P<0.05).The incidence rates of adverse reactions of chemotherapy in observation group and control group were 9.52%and 11.90%,respectively,there was no statistically significant difference between the two groups(P>0.05).Conclusion Paclitaxel combined with carboplatin regimen can effectively improve curative effect and promote decline of breast cancer pathological grade in neoadjuvant chemotherapy of triple-negative

关 键 词：紫杉醇卡铂方案 三阴性乳腺癌 新辅助化疗 病理变化 

分 类 号：R737.9[医药卫生—肿瘤]